• 1
    Partin AW, Pound CR, Pearson JD et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43 649 59
  • 2
    Lange PH, Ercole CJ, Lightner DJ et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141 873 9
  • 3
    Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996;47 232 5
  • 4
    Egawa S, Matsumoto K, Suyama K et al. Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy. Urology 1999;53 148 54
  • 5
    Cadeddu JA, Partin AW, DeWeese TL et al. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998;159 173 8
  • 6
    Schild SE, Buskirk SJ, Wong WW et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996;156 1725 9
  • 7
    Patel A, Dorey F, Franklin J et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158 1441 5
  • 8
    D’Amico AV & Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72 2638 43
  • 9
    Witherspoon LR & Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol 1997;157 1322 8
  • 10
    International Union Against CancerIn Sobin LH, Wittekind Ch eds, TNM Classification of Malignant Tumours, 5th edn, New York: John Wiley & Sons, Inc, 1997; 170 3
  • 11
    Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol 1999;161 163 8
  • 12
    Partin AW, Mohler JL, Piantadosi S et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45 831 8
  • 13
    Stamey TA, Graves HCB, Wehner N. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993;149 787 92
  • 14
    Nam RK, Klotz LH, Jewett MAS et al. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a ‘rapid riser’ subset. Br J Urol 1998;81 100 4
  • 15
    Gerber GS, Gornik HL, Goldfischer ER et al. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J Urol 1998;159 1243 6
  • 16
    Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer. Cancer 1993;71 2031 40
  • 17
    Egawa S, Suyama K, Matsumoto K et al. Improved predictability of extracapsular extension and seminal vesicle involvement based on clinical and biopsy findings in prostate cancer in Japanese men. Urology 1998;52 433 40
  • 18
    Kahn D, Williams RD, Manyak MJ et al. 111 Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 1998;159 2041 7